dihydro-α-ergocryptine
Sign in to saveAlso known as 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-9,10alpha-dihydroergotaman-3',6',18-trione, alpha-dihydroergocryptine, 9,10-dihydro-alpha-ergocryptine, 9,10-dihydro-α-ergocryptine, Dihydro-alpha-ergocryptine, Alpha-Dihydroergocriptine, Dihydroergocryptine, α-dihydroergocryptine
Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. It is taken by mouth.
Research
17 papers- Metabolism study of dihydro-alpha-ergocryptine,9,10-[9,10-3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes.American journal of therapeutics · 1997
- Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.Drugs & aging · 1992
- Identification of repurposed drugs targeting significant long non-coding RNAs in the cross-talk between diabetes mellitus and Alzheimer's disease.Scientific reports · 2022
- Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK).Neuroscience letters · 1994
- Hirschsprung's disease: catecholamine content, alpha-adrenoceptors, and the effect of electrical stimulation in aganglionic colon.Journal of pediatric surgery · 1986
via PubMed
~7 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Parkinson's disease
- Other uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- References
Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. It is taken by mouth.
==Medical uses==
Excerpted from Wikipedia’s “dihydro-α-ergocryptine” article, available under the CC BY-SA 4.0 licence.